Personalized cancer vaccines

Bibliography

• Jain KK. Textbook of Personalized Medicine. Springer, New York; 2009
   Google Scholar
• Jain KK. Cell therapy: technologies, markets and companies, Jain PharmBiotech Publications, Basel; 2010
   Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010;16:399-403
   PubMed Web of Science ®Google Scholar
• Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy 2009;1:19-25
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Vose JM, Czerwinski DK, Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:37-46
   PubMed Web of Science ®Google Scholar
• Hanna MG, Hoover HC, Pinedo HM, Finer M. Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer. Hum Vaccin 2006;2:185-91
   PubMed Web of Science ®Google Scholar
• Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 2004;3:521-7
   PubMedGoogle Scholar
• Wood CG, Mulders P. Vitespen: a preclinical and clinical review. Future Oncol 2009;5:763-74
   PubMed Web of Science ®Google Scholar
• Eton O, Ross MI, East MJ, Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med 2010;8:9
   PubMed Web of Science ®Google Scholar
• Ding Z, Wei Y. Therapeutic vaccine for melanoma: the untouched grail? Expert Rev Vaccines 2007;6:907-11
   PubMed Web of Science ®Google Scholar
• Janikashvili N, Larmonier N, Katsanis E. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy 2010;2:57-68
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Black KL. DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 2009;18:509-19
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK, Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005;174:3798-807
   PubMed Web of Science ®Google Scholar
• Roth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L) – telomerase-based cancer therapy. Recent Results Cancer Res 2010;184:221-34
   PubMedGoogle Scholar
• Koya RC, Kimura T, Ribas A, Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther 2007;15:971-80
   PubMed Web of Science ®Google Scholar
• Reinis M. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas. Curr Opin Mol Ther 2008;10:526-34
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57
   PubMed Web of Science ®Google Scholar
• Mackensen A, Meidenbauer N, Vogl S, Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006;24:5060-9
   PubMed Web of Science ®Google Scholar
• Merlo A, Turrini R, Dolcetti R, Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opin Biol Ther 2008;8:1265-94
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Yu Z, Theoret MR, Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70:6171-80
   PubMed Web of Science ®Google Scholar
• Cooper L, Ausubel L, Gutierrez M, Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 2006;8:105-17
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Holmes JP, Murray JL, CD4+ T cells in antitumor immunity: utility of an Ii-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther 2009;9:71-8
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Gilham DE, Debets R, Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther 2010;21:665-72
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Santos E, Nikhamin Y, Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13:5426-35
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Aebersold P, Cornetta K, Gene transfer into humans – immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. NEJM 1990;323:570-8
   PubMed Web of Science ®Google Scholar
• Wei Y, Sticca RP, Holmes LM, Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 2006;28:585-93
   PubMed Web of Science ®Google Scholar
• Pilla L, Rivoltini L, Patuzzo R, Multipeptide vaccination in cancer patients. Expert Opin Biol Ther 2009;9:1043-55
   PubMed Web of Science ®Google Scholar
• Norell H, Poschke I, Charo J, Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010;8:53
   PubMed Web of Science ®Google Scholar
• Benavides LC, Gates JD, Carmichael MG, The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009;15:2895-904
   PubMed Web of Science ®Google Scholar
• Patil R, Clifton GT, Holmes JP, Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a Phase I/II clinical trial. J Am Coll Surg 2010;210:140-7
   PubMed Web of Science ®Google Scholar
• Gates JD, Carmichael MG, Benavides LC, Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Am Coll Surg 2009;208:193-201
   PubMed Web of Science ®Google Scholar
• Perez SA, von Hofe E, Kallinteris NL, A new era in anticancer peptide vaccines. Cancer 2010;116:2071-80
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kakuma T, Uemura H, A randomized Phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010;59:1001-9
   PubMed Web of Science ®Google Scholar
• Pejawar-Gaddy S, Finn OJ. Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 2008;67:93-102
   PubMed Web of Science ®Google Scholar